Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STX-0712 in Advanced CMML and AML
NCT06950034Phase 1Recruiting
- Sponsor
- Solu Therapeutics
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of STX-0712 in chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML), sponsored by Solu Therapeutics. Primary endpoint: Maximum Tolerated Dose and/or Minimum Effective Dose at 12 months. Started Mar 2025; status: recruiting.
02
Drugs
STX-0712
03
Conditions
chronic myelomonocytic leukemia (CMML)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06950034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06950034.